The REVEAL-HBV cohort study in Taiwan showed that increased HBV DNA and ALT levels were predictive for cirrhosis and HCC risk in patients not taking antiviral treatment [15,30,31]. The gene discussed is GPT; the disease is hepatocellular carcinoma.